As the Pro Medicus share price drops 8%, should I buy more?

Is the healthtech darling going on sale after a record run?

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is putting on a rare display today.

Shares in the medical imaging software company have fallen on only four days over the past month. Barring an enormous afternoon rally, it appears we're on track for the fifth burgundy-tinged session for Pro Medicus shareholders.

As I write this article, shares are "rolling in the dee-ee-eep" (as Adele would say), down 8.5% to $245.66. Initially, that might sound rather devastating, but context is important. Even with today's blood-stricken performance, the Pro Medicus share price is still 154% better off than where it was situated at the end of 2023.

Why the fall?

Usually, an ASX announcement is the source of such a dramatic daily move. However, if we look at Pro Medicus' releases, we see a lot of nothing since Wednesday last week. Investors must be reacting to something other than news, then.

Without anything concrete to point to, we can only resort to presumptions. My best guess is that some people are choosing to crystallise part of their lucrative positions following a long stretch of exuberance surrounding Pro Medicus.

For example, if you'd invested $5,000 only two years ago into Pro Medicus, that amount would have been worth around $22,800 before today's opening bell. Pair this with an earnings multiple that looks lofty — at a price-to-earnings (P/E) ratio of 310 times — and it's not hard to see why there might be an appetite for profit-taking.

After all, co-founders Sam Hupert and Anthony Hall themselves cashed in about $256.7 million worth of shares last week.

Is the Pro Medicus share price tempting?

Fundamentally, Pro Medicus' valuation looks rich.

If we run some quick numbers, the company's free cash flow yield is around 0.3%. Think of the free cash flow yield as the cash the business pays you for your invested capital — sort of like the interest rate on a savings account.

Now, 0.3% isn't all that appealing compared to the 5% I could probably get on cash right now. Actually, it looks downright unsatisfactory. But that doesn't give us the whole picture. Future earnings ought to be considered, too.

That's where the water begins to get muddy, making it difficult to tell whether Pro Medicus is a good buy.

The company probably needs another decade of tremendous growth to justify its current valuation. Fortunately, the market opportunity for its picture archiving and communication system solutions in the United States might make that possible.

At the recent annual general meeting, Hupert stated:

We think about 85% [of the market] is addressable, including from both a product and commercial point of view. We now have about 7% of the market, a touch more. Doesn't sound like much, but America is a huge market, and no one has gone from 0% or standing start to 7% as quickly as we have.

Let's do some crude estimates based on the above… the last 12 months resulted in $161.5 million of revenue. It's not accurate, but let's just say this represents the 7% current market share. At 85%, it might suggest a 12-fold increase in revenue (85% divided by 7%) — equating to $1,961 million in annual revenue.

If I then assumed a 60% net margin, we'd probably be talking about $1,177 million in net profit. At a 25-times earning multiple, we'd arrive at a market capitalisation of $29.4 billion — approximately 15% higher than it is today.

Based on my rough napkin maths, I'd rather just hold onto my shares for now. However, if the Pro Medicus share price continues to fall, it might start to look interesting for adding to my position again.

Motley Fool contributor Mitchell Lawler has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall
Opinions

2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth

Shaw and Partners portfolio manager James Gerrish says he knows this will be an 'unpopular call'.

Read more »

Woman and man calculating a dividend yield.
Opinions

Buy or bail? Fundie's verdict on 2 ASX 300 shares

Stuart Bromley of Medallion Financial Group provides his insights.

Read more »

A woman sits in a quiet home nook with her laptop computer and a notepad and pen on the table next to her as she smiles at information on the screen.
Opinions

2 top ASX passive income stocks to buy with $5,000 today

I think these leading ASX passive income shares will keep delivering market beating yields in FY 2026.

Read more »

A black cat waiting to pounce on a mouse.
Opinions

ASX All Ords gold share jumps 28% in 7 days – but fundie says don't hold on

Niv Dagan of Peak Asset Management has a sell rating on this ASX All Ords gold stock.

Read more »

a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
Opinions

This ASX 200 share has made the most money for my portfolio. I'm expecting a lot more

There’s one key reason why I’m expecting strong growth from this stock.

Read more »

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face with an eyebrow raised and pursed lips.
Opinions

Is it time to be bullish or cautious on buying ASX shares right now?

Should investors be greedy or fearful as FY26 approaches?

Read more »

A happy young woman in a red t-shirt hold up two delicious burritos.
Opinions

Bull vs. Bear: Guzman Y Gomez shares

Guzman Y Gomez shares peaked at $45.99 in February and closed at $28.04 yesterday. Where to now?

Read more »

A businessman hugs his computer and smiles.
Opinions

3 ASX 200 shares to buy and hold forever

I don't expect these stocks to go out of style anytime soon.

Read more »